author-photo

Meena Thayu

Children's Hospital of Philadelphia
Janssen Pharmaceutica

54

Papers

1611

Citations

Citation Trend

Filter By

Papers (40) Sort By

Journal Conference Others

1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (11)
OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (14)
1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)
1247P Management of infusion-related reactions (IRRs) in patients receiving amivantamab

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic Non‒Small-Cell Lung Cancer: Brief Report on a Randomized, Open-label, Phase 1b/2 Study (LUC2001 JNJ-54767414)

2020
Show All
- Source
- Cite
- Save
Citations (0)
Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (42)